Iambic Therapeutics is disrupting the therapeutics landscape with its unique AI-driven drug-discovery platform. Iambic has assembled a world-class team that unites pioneering AI experts and experienced drug hunters with strong track records of success in delivering clinically validated therapeutics. The Iambic platform has been demonstrated to deliver high-quality, differentiated therapeutics to clinic with unprecedented speed and across multiple target classes and mechanisms of action. The Iambic team is advancing an internal pipeline of clinical assets to address urgent unmet patient needs. Learn more about the Iambic team, platform, and pipeline at iambic.ai.
Location: United States, California, San Diego
Employees: 51-200
Total raised: $150M
Founded date: 2019
Investors 3
| Date | Name | Website |
| 25.10.2023 | OrbiMed | orbimed.co... |
| 27.01.2024 | Shanda Gro... | shanda.com |
| - | Catalio Ca... | cataliocap... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 19.06.2024 | Series B | $50M | - |
| 06.10.2023 | Series B | $100M | - |
Mentions in press and media 4
| Date | Title | Description |
| 26.09.2024 | Lundbeck and Iambic Therapeutics announce strategic partnership to leverage AI for drug discovery | Lundbeck and Iambic Therapeutics announce strategic partnership to leverage AI for drug discovery Thu, Sep 26, 2024 12:00 CET Report this content Lundbeck partners with Iambic to utilize its AI-powered drug discovery platform to accelerate ... |
| 19.06.2024 | Iambic Therapeutics Raises $50M in Series B Extension Funding | Iambic Therapeutics, a San Diego, CA-based clinical-stage biotechnology company, raised $50M in Series B extension funding. The round was led by Mubadala Capital and Exor Ventures, with participation from Qatar Investment Authority (QIA), a... |
| 06.10.2023 | Iambic Therapeutics Closes $100M Series B Financing | Iambic Therapeutics (formerly known as Entos), a San Diego, CA-based biotechnology company developing novel therapeutics from its generative AI discovery platform, closed a $100m Series B financing. The round was co-led by Ascenta Capital a... |
| 03.10.2023 | Iambic Therapeutics raises $100M in Series B funding to advance multiple candidates into clinical development, expand their pipeline, and continue building next-gen AI technologies for drug discovery | - |